SCHEMBL6929247

SCHEMBL6929247

N#Cc1ccccc1Oc1ccc(CC2CCNCC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.51
POLB P06746 1/20 0.50
GAA P10253 1/20 0.50
SLC6A2 P23975 6/20 0.47
SLC6A4 P31645 6/20 0.47
SLC6A3 Q01959 5/20 0.47
KCNH2 Q12809 3/20 0.46
LPAR1 Q92633 1/20 0.44
LPAR5 Q9H1C0 1/20 0.44
MAPK14 Q16539 3/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
HTR1A P08908 2/20 0.42
SCN9A Q15858 1/20 0.42
EZH2 Q15910 1/20 0.41
CYP3A4 P08684 1/20 0.41
HTR3A P46098 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6929244 0.82 GBA1 (0.43) GBA1POLBGAASLC6A2SLC6A4
SCHEMBL6926396 0.81 SLC6A2 (0.52) GBA1SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL6926483 0.80 GBA1 (0.55) GBA1SLC6A2SLC6A4SLC6A3LPAR1
SCHEMBL7526770 0.79 GBA1 (0.71) GBA1SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL6926391 0.78 SLC6A4 (0.54) GBA1SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL6927394 0.78 GBA1 (0.53) GBA1SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL6928758 0.78 AR (0.42) GBA1SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL6927185 0.77 MGLL (0.50) GBA1SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL6922640 0.77 GBA1 (0.51) GBA1SLC6A2SLC6A4SLC6A3LPAR1
SCHEMBL3251596 0.76 SLC6A2 (0.50) SLC6A2SLC6A4SLC6A3KCNH2HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6518284-B2 For inhibiting the serotonin and/or noradrenaline reuptake, and are useful as medicaments in disorders in which an increase of levels of those neurotransmitters is necessary FAES, FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS S.A. (ES) 2003-02-11 US claimed
US-20020038031-A1 New 4 - substituted piperidines ORJALES VENERO AURELIO (ES) 2002-03-28 US claimed
EP-1002794-A1 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors FAES, Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A. (ES) 2000-05-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020038031-A1 New 4 - substituted piperidines ADRA2C, ADRB2, ADRB1 GBA1 1368/4885POLB 2053/4885GAA 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.